Strategic Partnerships · Licensing · Joint Ventures

The Future of
Periodontal Health
Starts Here.

PerioRex™ is advancing patent-protected science for periodontal health — one of healthcare's largest unmet needs. Built on published clinical research and MFDS functional ingredient recognition, our platform creates opportunities for licensing, strategic partnerships, and commercial expansion across U.S. healthcare markets.

Partner With Us → View Opportunity →
✓
Patent-protected platform technology Science-led development for the future of periodontal health
Periodontal health — teeth and gum tissue with molecular science overlay
4
Peer-Reviewed Studies
n=94
Human Clinical Trial (RCT)
5
Patents (US · KR · JP)
Mar 2025
MFDS Functional Recognition
7 yrs
R&D at Korean University Hospitals

The U.S. Market Opportunity

A large, underserved market with clear demographic tailwinds

Periodontal disease is one of the most prevalent, and most economically burdensome, chronic conditions in the United States. Prevalence rises sharply with age, and America's aging population is expanding the addressable market year over year.

Twelve diverse Americans showing signs of dental discomfort — periodontal disease affects every age, ethnicity, and background across the U.S.
90M+ Americans affected — across every age, ethnicity, and background
🦷
42.2%
U.S. adults 30+suffer from periodontitis
◈
60%
Adults aged 65+are affected by periodontitis
△
7.8%
U.S. adults 30+have severe periodontitis
◉
90M
Americansestimated to be affected
Market Scale & Economic Impact
✚
37.3M
Seniors 65+ affected by periodontitisfrom a rapidly growing 62.2M senior demographic
$
$189B
U.S. dental care markettotal expenditures in 2024
%
$154B
Annual economic burdenof periodontal disease in the U.S.
Sources: Data cited from the U.S. Centers for Disease Control and Prevention (CDC) and the National Institute of Dental and Craniofacial Research (NIDCR). U.S. population and dental expenditure figures reflect the most recent publicly available data through 2024. Estimated seniors affected by periodontitis calculated based on 60% prevalence applied to the 62.2M U.S. population aged 65+.

Revenue Potential

Estimated annual revenue at varying market share

Even modest market penetration into a 90M-person addressable market represents a meaningful, scalable revenue opportunity for U.S. partners.

Assumption: Average purchase of US$25 per month per customer  ·  US$300 per year
U.S. Market Share
Estimated Customers
Estimated Annual Revenue
0.1%
90,000
US$27 Million
0.5%
450,000
US$135 Million
1.0%
900,000
US$270 Million
5.0%
4.5 Million
US$1.35 Billion

Illustrative projections based on a total addressable population of approximately 90 million Americans affected by periodontitis. Actual results will depend on distribution reach, pricing, marketing investment, and category-level uptake.

Why PerioRex

A defensible science platform in a category short on innovation

PerioRex™ is being developed to address one of healthcare's largest unmet needs. Built on patent-protected technology and rigorous scientific research, the platform advances periodontal health innovation in a category where — despite tens of millions of Americans affected — very few daily-use offerings have completed peer-reviewed clinical research.

For leading U.S. healthcare, oral care, and consumer health companies, PerioRex represents an attractive platform for strategic partnership, licensing, and joint venture collaboration.

§
Patent-Protected IP

US Patent No. US 10,022,412 B2 plus additional patents in Korea and Japan covering the Propolis + Mangosteen composition for periodontal use.

◎
Human Clinical Validation

Double-blind, placebo-controlled RCT (n=94) conducted at Ajou University and Seoul St. Mary's Hospital, published in Nutrients (SCIE) in 2024.

✚
Government-Recognized Functional Ingredient

Korea MFDS functional ingredient recognition (March 2025) — the Korean equivalent of a qualified health claim, with the approved claim "may help alleviate gum condition."

↗
Category Whitespace

The daily-use periodontal health category lacks products with the same combination of clinical evidence, patent protection, and regulatory endorsement.

A patent-protected science platform, ready for U.S. commercialization

Seven years of R&D. Four peer-reviewed publications. Two independent human clinical trials at major Korean university hospitals. One government-recognized functional ingredient. Positioned for U.S. market entry through strategic partnership.

Strategic Partnership Licensing Joint Venture Private Label Co-Development
PerioRex — Advanced Oral Health packaging: box and bottle, 60 capsules, GMP-manufactured dietary supplement

The Product

Advanced Oral Health. Ready for U.S. commercialization.

PerioRex offers a fully-developed daily oral health product — GMP-manufactured, built around the patented Propolis + Mangosteen complex, and supported by a double-blind human clinical trial and MFDS functional ingredient recognition. Packaging, formulation, and full regulatory dossier are complete and ready for U.S. launch through strategic partnership, licensing, or private label.

Format 60 capsules · daily dietary supplement
Active Propolis + Mangosteen complex · US Patent 10,022,412 B2
Manufacturing GMP-certified · Made in Korea
Regulatory Full dossier · MFDS functional ingredient recognition (2025)
Available Under Strategic partnership · Licensing · Private label

Clinical Evidence

A rigorous scientific foundation

Seven years of research — from in vitro cell studies to a double-blind randomized controlled trial in adults — published across 4 SCIE-indexed peer-reviewed journals.

01
Randomized Double-Blind Placebo-Controlled Trial · 2024
Clinical effect of Propolis + Mangosteen complex in adults with gingivitis — 8-week RCT, n=94, conducted at Ajou University & Seoul St. Mary's Hospital
↓ PGE₂, IL-1β (inflammation biomarkers) ↓ MMP-8, MMP-9 (tissue destruction markers) Double-blind · Placebo-controlled · 94 subjects
Nutrients (SCIE), 16(17):3000 (2024)
02
In Vitro Study · 2020
Anti-inflammatory and bone formation effects of Garcinia mangostana L. and propolis extracts in human gingival and osteoblast-like cells
↓ IL-6, IL-8, PGE₂ (inflammation) ↑ RUNX2, COL1A1, Osteocalcin (bone formation) ↑ ALP activity & bone mineralization
Food Science and Biotechnology (SCIE), 29(4):539–548 (2020)
03
Animal Study · 2019
Inhibition of inflammation and alveolar bone loss in ligature-induced periodontitis in mice — 3-week daily oral administration
↓ PGE₂, IL-8, iNOS, COX-1, COX-2 ↓ MMP-8 (gum tissue destruction marker) Alveolar bone loss inhibited
International Journal of Oral Biology (SCIE), 44(2):55–61 (2019)
04
Animal Study · 2021
Alveolar bone loss inhibition under high-inflammation conditions (20× LPS stress) — dose-response confirmed in mouse periodontitis model
24.3% bone loss inhibition at standard dose 28.9% inhibition at double dose Effective under extreme inflammatory stress
Korean Journal of Dental Materials, 48(2):71–78 (2021)
✚

Korea MFDS Functional Ingredient Recognition — March 2025

Certificate No. 2025-13 · Issued by the Ministry of Food and Drug Safety, Republic of Korea, March 25, 2025. The Propolis + Mangosteen complex is officially recognized as a functional ingredient with the approved health claim: "May help alleviate gum condition." Recognition followed full clinical dossier review including two independent human clinical trials conducted at major Korean university hospitals. This is the Korean equivalent of a GRAS or qualified health claim — the highest level of functional food ingredient recognition in Korea.

🇺🇸

United States Patent

US 10,022,412 B2

Composition for preventing/improving periodontal disease using mangosteen extract

🇰🇷

Korea — 3 Patents

10-17775613 · 10-1879398 · 10-1989971

Periodontal disease prevention, bone formation promotion, and root canal compositions

🇯🇵

Japan Patent

6387467

Composition for preventing/improving periodontal disease using mangosteen extract

DL

Mr. Daesung Lee

Co-CEO & Founder

Former Professor
College of Pharmacy
Seoul National University

The Team Behind PerioRex

Decades of pharmaceutical research, ready for U.S. commercialization

PerioRex™ is developed by Medibio Lab Co., Ltd., a GMP-certified Korean biotechnology firm founded by Mr. Daesung Lee — former Professor at Seoul National University College of Pharmacy, Korea's most prestigious pharmaceutical institution. The company is officially certified as a biotechnology enterprise by a Korean government-affiliated institute dedicated to advancing the biotechnology industry.

Following seven years of intensive R&D, four peer-reviewed SCIE-indexed publications, two independent human clinical trials at major Korean university hospitals, and issued patents across the United States, Korea, and Japan, PerioRex is now ready for U.S. market entry through strategic partnership.

Business Opportunity

Partnership pathways for U.S. market entry

We are selectively engaging leading U.S. healthcare, oral care, and consumer health companies. Multiple partnership models are available — structured around your capabilities, distribution, and strategic priorities.

◈

Strategic Partnership

Long-term commercial partnerships with established healthcare, oral care, and consumer health leaders.

  • Co-marketing & co-branding
  • Preferred distribution rights
  • Category exclusivity available
  • Full scientific dossier access
§

Licensing

License the patented Propolis + Mangosteen composition for use in your own branded product line.

  • US Patent No. 10,022,412 B2
  • Territory-based licensing terms
  • Full technical & regulatory package
  • MFDS documentation included
⚙

Joint Venture

Co-invested U.S. commercialization entity with shared upside for scale-up and market development.

  • Shared equity structure
  • Combined U.S. manufacturing & distribution
  • Joint brand development
  • Multi-channel go-to-market
✚

Healthcare & Dental

Positioned for dental service organizations, dental supply distributors, and healthcare-adjacent brands.

  • Dental Service Organizations (DSOs)
  • Periodontal specialty practices
  • Insurance-adjacent wellness programs
  • Dental hygiene & supply channels
◎

Oral Care Brands

Extend leading oral care brand portfolios into the daily periodontal supplement category — a whitespace opportunity.

  • Category-adjacent line extension
  • Retail-ready formulation
  • Clinical positioning support
  • Private label available
◇

Pet Health Companies

The same patented complex is already commercialized as PerioRex Pet™ for companion animals — cross-category partnership opportunities available.

  • Human + pet portfolio synergy
  • Shared manufacturing & sourcing
  • Cross-marketing opportunities
  • Pet-vertical exclusivity available

Let's discuss how PerioRex fits your U.S. growth strategy

We are actively evaluating strategic partners, licensees, and joint venture candidates. The full scientific dossier, patent documentation, MFDS certification, and business plan are available on request under NDA.

Request Partnership Packet → info@periorex.com

Business Development

Start the conversation

Whether you are exploring a strategic partnership, licensing agreement, joint venture, or private label arrangement, we would welcome the opportunity to discuss how PerioRex™ fits your growth strategy in the U.S. market.

✉
Business Development info@periorex.com
◉
Headquarters 25-11 Palpan-gil, Jongno-gu, Seoul, Republic of Korea
§
Available Under NDA Business Plan · Product Brochure · Scientific Papers · Clinical Trial Reports · MFDS Certificate · Patent Documentation · Manufacturing & GMP Certificates · Financial Projections
✚
Developed & Manufactured By Medibio Lab Co., Ltd. — Korean Biotechnology Firm · GMP Certified · Seoul, Korea

Partnership Inquiry